EQ102 / Equillium - LARVOL DELTA

A Randomized, Double-blind, Placebo-controlled Phase I Study of Subcutaneous EQ102 Administered in a Single and Multiple Ascending Dose Schedule (ANZCTR) - P1 | N=72 | Completed | Sponsor: Equillium AUS PTY Ltd | Recruiting ➔ Completed

Trial completion • Celiac Disease • Immunology

A Randomized, Double-blind, Placebo-controlled Phase I Study of Subcutaneous EQ102 Administered in a Single and Multiple Ascending Dose Schedule (ANZCTR) - P1 | N=64 | Recruiting | Sponsor: Equillium AUS PTY Ltd | Initiation date: Sep 2000 ➔ Sep 2022

Trial initiation date • Celiac Disease • Immunology

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates (Businesswire) - "EQ101: Phase 2 clinical study in subjects with alopecia areata – initial data anticipated in 2H 2023, topline data anticipated in mid-2024; EQ102: Phase 1 first-in-human study in healthy volunteers and subjects with celiac disease – single ascending dose/multiple ascending dose data anticipated in 2H 2023, celiac disease patient data anticipated in 2024..."

P1 data • P2 data • Acute Graft versus Host Disease • Alopecia • Celiac Disease • Graft versus Host Disease • Immunology • Lupus Nephritis

γc receptor antagonist, EQ102, prevents the NK and T cell-mediated responses driven by IL-15 and IL-21 (P854) (IMMUNOLOGY 2023) - "EQ102 treatment effectively inhibits the IL-15/IL-21 co-stimulatory cytolytic responses of these cell populations. These results suggest that selective blockade of IL-15 and IL-21 by EQ102 inhibits the synergistic signaling that mediates NK and T cell responses in multiple immune disorders."

Immune Modulation • Immunology • Inflammation • IFNG • IL15 • IL21

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists (Businesswire) - "Equillium, Inc...today announced a poster was presented over the weekend at IMMUNOLOGY2023, the annual meeting of The American Association of Immunologists. The meetings are taking place at the Walter E. Washington Convention center in Washington, DC, May 11 – 15....EQ102 is a multi-cytokine inhibitor that selectively blocks IL-15 and IL-21 signaling while preserving signaling of other γc family members. Co-stimulation of IL-15 and IL-21 enhanced proliferation, activation, and IFNγ, Granzyme A, Granzyme B and Perforin production above single cytokine conditions and EQ102 treatment effectively inhibits the IL-15/IL-21 co-stimulatory cytolytic responses of these cell populations. Results suggest that selective blockade of IL-15 and IL-21 by EQ102 inhibits the synergistic signaling that mediates NK and T cell responses in multiple immune disorders."

Preclinical • Acute Graft versus Host Disease • Celiac Disease • Graft versus Host Disease • Immunology • Inflammatory Bowel Disease

Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference (Businesswire) - "Equillium, Inc...announced data presented at the annual La Jolla Immunology Conference. The research highlights the potential for multi-cytokine inhibitors such as EQ101 and EQ102, as potentially effective strategies for the treatment of certain autoimmune diseases....'We look forward to initiating a Phase 2 clinical study of EQ101 in subjects with alopecia areata, and a Phase 1 first-in-human study of EQ102 in normal healthy volunteers – as well as celiac patients – both by the end of this year.'"

Clinical data • New P1 trial • New P2 trial • Acute Graft versus Host Disease • Alopecia • Celiac Disease • Dermatology • Graft versus Host Disease • Immunology